Source-grounded facts extracted from OmniAb, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
OmniAb, Inc. reported the three months ended March 31, 2026 results: revenue $14.4 million. Guidance raised.
“as demonstrated by the launch of OmniUltra TM and our xPloration ® partner access program. ” First Quarter 2026 Financial Results Revenue for the first quarter of 2026 was $14.4 million , compared with $4.2 million for the same period in 2025 , with the increase primarily related to milestone revenue . Research and development expense was $9.6 million for the”
OmniAb, Inc.: Amended and restated bylaws to address universal proxy rules and modernize stockholder meeting procedures (effective 2026-01-30).
“On January 30, 2026, the Board of Directors (the “Board”) of OmniAb, Inc. (the “Company”) approved and adopted amended and restated bylaws (the “Amended and Restated Bylaws”), which became effective the same day.”
Philip J. Gotwals was appointed as Director at OmniAb, Inc..
“the Board appointed Steven C. Crouse and Philip J. Gotwals, Ph.D. to the Board”
Steven C. Crouse was appointed as Director at OmniAb, Inc..
“the Board appointed Steven C. Crouse and Philip J. Gotwals, Ph.D. to the Board”
Joshua Tamaroff resigned as Director at OmniAb, Inc..
“On June 27, 2024, Joshua Tamaroff resigned from the Board of Directors (the “Board”) and Audit Committee of the Board (the “Audit Committee”) of OmniAb, Inc. (the “Company”), effective June 28, 2024, due to his pending departure from Avista Capital Partners.”
OmniAb, Inc. reported the first quarter of 2024 results: revenue $3.8 million, net income $19.0 million net loss, EPS $0.19 per share loss.
“to continued progress by our partners and expansion of our technology as the year progresses.” First Quarter 2024 Financial Results Revenue for the first quarter of 2024 was $3.8 million, compared with $16.9 million for the same period in 2023, with the decrease primarily due to the recognition in the 2023 period of a $10 million milestone related to the first”
OmniAb, Inc. reported the three months ended March 31, 2024 results: revenue $3.8 million, net income $19.0 million net loss, EPS $0.19 per share loss.
“to continued progress by our partners and expansion of our technology as the year progresses.” First Quarter 2024 Financial Results Revenue for the first quarter of 2024 was $3.8 million, compared with $16.9 million for the same period in 2023, with the decrease primarily due to the recognition in the 2023 period of a $10 million milestone related to the first”
OmniAb, Inc. reported 12 months ended December 31, 2023 results: revenue $34.2 million, net income $50.6 million, EPS $0.51 per share.
“or $0.14 per diluted share, compared with net income of $6.8 million, or $0.07 per share, for the same period in 2022. Full Year 2023 Financial Results Revenue for 2023 was $34.2 million, compared with $59.1 million for 2022, with the decrease primarily due to the recognition of TECVAYLI ® milestones of $10.0 million in 2023 compared with $25.0 million in 2022.”
OmniAb, Inc. reported three months ended December 31, 2023 results: revenue $4.8 million, net income $14.1 million, EPS $0.14 per diluted share.
“as we are now staffed and resourced to efficiently leverage the future growth of the business.” Fourth Quarter 2023 Financial Results Revenue for the fourth quarter of 2023 was $4.8 million, compared with $35.3 million for the same period in 2022, with the decrease primarily due to the recognition of a $25.0 million milestone payment in the prior-year period related”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.